Invite Adam To Speak
Adam is retained to speak by corporate governance organizations, corporate boards, law firms, audit/consulting firms, investor relations organizations, and investor conferences.
Topics include: small-cap boardroom best practices, capital markets, corporate finance, hiring/managing professional service providers, small-cap enterprise risk management, and small-cap board composition.
Most Board Members Underestimate Two Key Risks
Seated and prospective board members commonly focus on one key risk of being a public company board member that isn’t statistically significant, and ignore two of the biggest risks they actually face.
In Case You Missed It:
Everything You Wanted to Know About Microcap Boards
To wit: "Despite microcap public companies’ importance in our capital markets, there is a paucity of studies examining their board composition and governance practices. This study provides insights into the current governance landscape in this asset class."
For exclusive buy-side insights from Adam J. Epstein
November 15, 2018, Phoenix, AZ
Financial Executives International
"The Underappreciated Nexus Between Growth Capital and Storytelling… An Investor’s Perspective"
- Whether your company is public or private, family-owned or non-profit, growth capital is likely in your future.
- Finance executives have been trained to believe that equity or debt financing comes down to financial metrics — full stop.
- Regarding that long-held belief, former institutional investor, best-selling author, and acclaimed speaker Adam J. Epstein has the following question: “If equity and debt financings were just about dollars and cents, then how does that explain the fact that similarly performing companies are valued completely differently by investors and lenders every day?”
Join us for a frank, entertaining, interactive discussion.
Third Creek Advisors
How Hedge Funds Benefit from Investment Banking Conflict of Interests
Hear from a former institutional investor about how unavoidable financing conflicts of interest benefit hedge funds… not issuers.